InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.04
(
0.02%
)
Bitcoin
63,035.47
(
-0.20%
)
Post# of 252311
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ghmm

Send PM Follow Ignore
Followers 50
Posts 6343
Boards Moderated 0
Alias Born 01/22/2006

ghmm

Re: jq1234 post# 219445

Wednesday, 06/06/2018 2:01:37 PM

Wednesday, June 06, 2018 2:01:37 PM

Post# of 252311
BMY / NKTR / MRK NSCLC:


As crazy as BMY had been in NSCLC trial design especially CheckMate-227, I don’t think they’d be crazy enough to try to run Opdivo directly against Keytruda in any way/trial anytime soon.


What do you think of a Opdivo+214+Chemo? Then if it does poor they blame 214 and if 214 is active has a chance to beat Keytruda?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up